Patent intelligence · US
US 12384845
Activatable masked anti-CTLA4 binding proteins
Activatable masked anti-CTLA4 binding proteins
Patent details — US 12384845
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Applicant
- Xilio Development, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K47/6849, A61P
Quick answer
US 12384845 (Activatable masked anti-CTLA4 binding proteins) is held by Xilio Development, Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Xilio Development, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K47/6849, A61P, A61P35/00
More from Xilio Development, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12280120
Tumor-specific cleavable linkers
granted -
US 11866476
Masked IL-2-Fc fusion polypeptides
granted -
US 11827686
Masked cytokine polypeptides
granted -
US 11827685
Masked cytokine polypeptides
granted -
US 11718655
Masked interleukin-12 polypeptides
granted -
US 11053294
Masked cytokine polypeptides
granted
Frequently asked questions
What is US patent 12384845?
US 12384845 (Activatable masked anti-CTLA4 binding proteins) is held by Xilio Development, Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12384845?
Xilio Development, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12384845 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.